Genetic Illness Surge Fuels Sanger Sequencing Market Growth Emerges as a Core Driver of the Sanger Sequencing Market in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Sanger Sequencing Market Through 2025?
The scope of the Sanger sequencing market has experienced swift expansion across recent years, projecting an increase from its 2024 valuation of $2.75 billion to $3.29 billion in 2025, reflecting a compound annual growth rate (CAGR) of 19.5%. This upward trajectory during the preceding years was fueled by several key factors, including a heightened need for research activities, a rise in medical diagnostic procedures, accelerated progress in pharmaceutical creation, broader application within agriculture, more extensive forensic examinations, the discovery of new biomarkers, and deeper scholarly investigation into genetic evolution.

What's the Projected Size of the Global Sanger Sequencing Market by 2029?
Anticipation surrounds the sanger sequencing market, which is projected for substantial expansion in the approaching years, reaching a valuation of $6.14 billion by 2029, propelled by a compound annual growth rate (CAGR) of 16.9%. This foroming surge in market size is fundamentally driven by several key factors: the accelerating incorporation of clinical genomics practices, the broadening scope of agricultural genomics, heightened emphasis on drug safety and pharmacogenomics, an uptick in prenatal and newborn screening initiatives, and the increasing frequency of environmental DNA analysis. Within this forecast timeframe, significant market dynamics are expected to materialize, such as continuous technological innovation, a mounting need for next-generation sequencing solutions, the proliferation of applications within clinical diagnostics, escalating financial commitments toward genomics research, and the wider adoption of personalized medicine approaches.

View the full report here:
https://www.thebusinessresearchcompany.com/report/sanger-sequencing-global-market-report

Top Growth Drivers in the Sanger Sequencing Industry: What's Accelerating the Market?
Anticipated escalation in the prevalence of genetic disorders is projected to fuel the expansion of the sanger sequencing market in the foroming period. A genetic illness, also termed a genetic disorder, represents a health affliction stemming from irregularities or alterations within a person's DNA, which constitutes the inherited material conveying genetic instructions. Sanger sequencing techniques are employed in identifying these genetic conditions by establishing the precise sequence of nucleotides, the foundational units of DNA, within a designated gene or segment of the genetic code. To illustrate this impact, as reported by the National Health Service, which is the publicly financed healare entity in the UK, approximately 2,300 people across the UK were documented as having thalassaemia in August 2024, with roughly 800 of those individuals afflicted by the severe manifestation of the disease, necessitating continuous blood transfusions; consequently, this increasing incidence of genetic diseases is directly stimulating the expansion of the sanger sequencing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13925&type=smp

What Trends Will Shape the Sanger Sequencing Market Through 2029 and Beyond?
Leading enterprises within the sanger sequencing industry are currently concentrating efforts on broadening their genomic laboratory footprints to supply expedited sanger sequencing capabilities across the northern regions of the United Kingdom. These genomic laboratories constitute dedicated centers for processing genetic material, carrying out tests and analyses crucial for examining the composition, operational roles, and hereditary transmission of genes and entire genomes, frequently supporting needs in medical diagnostics, scientific investigation, and tailored patient treatments. To illustrate, in the month of June 2023, Source Genomics, a service provider situated in the UK, announced the augmentation of its genetic testing facility into the northern sector of the nation, a move projected to amplify the throughput of their Sanger sequencing offerings and significantly reduce the time required to return analytical results. Such an extension of lab functions into northern territories represents a substantial stride toward guaranteeing fair availability of genomic solutions for research bodies throughout the nation, permitting clients from distant areas to access superior Sanger sequencing services accompanied by enhanced speed in result generation.

What Are the Main Segments in the Sanger Sequencing Market?
The sanger sequencingmarket covered in this report is segmented -

1) By Sequencing: Shotgun Sequencing; Targeted Gene Sequencing; Other Sequencing
2) By Laboratory: Wet Labs; Dry Labs
3) By Research: In-House; Outsourced
4) By Application: Diagnostics; Biomarkers and Cancer; Reproductive Health; Personalized Medicine; Forensics; Other Applications
5) By End User: Academic; Government Research Institutes; Pharmaceutical Companies; Biotechnology Companies; Hospitals; Clinics

Subsegments:
1) By Shotgun Sequencing: Whole Genome Shotgun Sequencing; Metagenomic Shotgun Sequencing
2) By Targeted Gene Sequencing: Amplicon Sequencing; Exome Sequencing
3) By Other Sequencing: Nested PCR Sequencing; Sequencing By Synthesis (SBS)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13925&type=smp

Which Top Companies are Driving Growth in the Sanger Sequencing Market?
Major companies operating in the sanger sequencing market report are Hoffmann-La Roche, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific, Illumina Inc., Beckman Coulter, PerkinElmer Inc., BGI Group, LGC Limited, GenScript, Oxford Nanopore Technologies, Pacific Biosciences of California Inc., Macrogen Inc., GENEWIZ Inc., Quintara Biosciences, CeMIA SA, Source BioScience, Microsynth AG, Fasteris SA, GenHunter Corporation, Nucleics Pty. Ltd., SciGenom Labs Pvt. Ltd., StarSEQ GmbH, GATC Biotech AG, Agilent Technologies

Which Regions Will Dominate the Sanger Sequencing Market Through 2029?
North America was the largest region in the sanger sequencing market in 2024. The regions covered in the sanger sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13925

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.